5:20 PM
 | 
Mar 22, 2013
 |  BC Extra  |  Financial News

Anacor still climbing on Phase II dermatitis data

Anacor Pharmaceuticals Inc. (NASDAQ:ANAC) gained an additional $1.24 (26%) to $6.08 on Friday after reporting data on Thursday from the Phase II AN2728-AD-204 trial evaluating AN2728 to treat atopic dermatitis. The stock jumped 26% on Thursday on the data....

Read the full 184 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >